Published in Br J Pharmacol on April 01, 2012
Expression and extracellular release of a functional anti-trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microb Cell Fact (2012) 0.97
Delivery of a functional anti-trypanosome Nanobody in different tsetse fly tissues via a bacterial symbiont, Sodalis glossinidius. Microb Cell Fact (2014) 0.85
Pre-existing differences and diet-induced alterations in striatal dopamine systems of obesity-prone rats. Obesity (Silver Spring) (2016) 0.80
Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model. Mol Ther (2014) 0.77
TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers. PLoS One (2014) 0.76
Camelid Single-Domain Antibodies As an Alternative to Overcome Challenges Related to the Prevention, Detection, and Control of Neglected Tropical Diseases. Front Immunol (2017) 0.75
Nanobodies As Tools to Understand, Diagnose, and Treat African Trypanosomiasis. Front Immunol (2017) 0.75
AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging (2003) 8.56
Isolation of salivarian trypanosomes from man and other mammals using DEAE-cellulose. Exp Parasitol (1970) 8.21
Naturally occurring antibodies devoid of light chains. Nature (1993) 7.35
Identification, purification and properties of clone-specific glycoprotein antigens constituting the surface coat of Trypanosoma brucei. Parasitology (1975) 7.22
Blood volume in the rat. J Nucl Med (1985) 3.40
Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem (1984) 3.39
Small animal SPECT and its place in the matrix of molecular imaging technologies. Phys Med Biol (2005) 2.68
Chemotherapy of human African trypanosomiasis: current and future prospects. Trends Parasitol (2003) 2.58
Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite. Adv Parasitol (2001) 2.45
Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest (2004) 2.39
Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J (1998) 2.30
Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother (2001) 2.24
Neurotransmitters and neuromodulators controlling the hypoxic respiratory response in anaesthetized cats. J Physiol (1999) 1.82
Microdialysis--theory and application. Prog Neurobiol (1990) 1.77
NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis (2010) 1.55
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem (2003) 1.54
Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum (2006) 1.50
An ultrastructural analysis of tissue surrounding a microdialysis probe. J Neurosci Methods (1999) 1.49
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med (2008) 1.45
Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol (2005) 1.41
Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer (2002) 1.36
Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease. J Clin Invest (2006) 1.24
Structural characterization of the asparagine-linked oligosaccharides from Trypanosoma brucei type II and type III variant surface glycoproteins. J Biol Chem (1991) 1.24
Cerebral vessel laminins and IFN-gamma define Trypanosoma brucei brucei penetration of the blood-brain barrier. J Clin Invest (2004) 1.23
Functional heavy-chain antibodies in Camelidae. Adv Immunol (2001) 1.22
Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med (2006) 1.20
Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J (2001) 1.19
Trypanosoma brucei brucei crosses the blood-brain barrier while tight junction proteins are preserved in a rat chronic disease model. Neuropathol Appl Neurobiol (2001) 1.18
Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm Res (1993) 1.18
Spread of Trypanosoma brucei to the nervous system: early attack on circumventricular organs and sensory ganglia. J Neurosci Res (1988) 1.15
Migration of African trypanosomes across the blood-brain barrier. Physiol Behav (2007) 1.13
Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Brain Res Rev (1997) 1.13
African trypanosome infections of the nervous system: parasite entry and effects on sleep and synaptic functions. Prog Neurobiol (2009) 1.12
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol (2008) 1.12
Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information. Eur J Nucl Med Mol Imaging (2009) 1.09
Expression and role of CXCL10 during the encephalitic stage of experimental and clinical African trypanosomiasis. J Infect Dis (2009) 1.09
Pentamidine movement across the murine blood-brain and blood-cerebrospinal fluid barriers: effect of trypanosome infection, combination therapy, P-glycoprotein, and multidrug resistance-associated protein. J Pharmacol Exp Ther (2009) 1.09
P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. J Infect Dis (2004) 1.08
The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem (2005) 1.08
The blood-brain barrier significantly limits eflornithine entry into Trypanosoma brucei brucei infected mouse brain. J Neurochem (2008) 1.07
Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med (2010) 1.07
Use of osmotic agents in microdialysis studies to improve the recovery of macromolecules. J Pharm Sci (2003) 1.07
High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog (2011) 1.01
Quantitative examination of tissue concentration profiles associated with microdialysis. J Neurochem (1992) 1.00
In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med (2010) 0.99
Kinetic analysis of novel mono- and multivalent VHH-fragments and their application for molecular imaging of brain tumours. Br J Pharmacol (2010) 0.98
Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold. Protein Sci (2004) 0.97
Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. J Immunol Methods (2007) 0.97
Neurochemical and morphological responses to acutely and chronically implanted brain microdialysis probes. J Neurosci Methods (1998) 0.97
Intracerebral dialysis and the blood-brain barrier. J Neurochem (1995) 0.95
Variant specific antigens of Trypanosoma brucei exist in solution as glycoprotein dimers. Biochem J (1981) 0.94
Changes in blood-brain barrier permeability associated with insertion of brain cannulas and microdialysis probes. Brain Res (1998) 0.94
Quantitative assessment of blood-brain barrier damage during microdialysis. J Pharmacol Exp Ther (1996) 0.93
Trypanosomiasis and the brain. Parasitology (2009) 0.91
Blood-brain barrier damage in experimental African trypanosomiasis. Ann Trop Med Parasitol (1994) 0.90
Control and function of the bloodstream variant surface glycoprotein expression sites in Trypanosoma brucei. Int J Parasitol (2001) 0.88
Magnetic resonance imaging to assess blood-brain barrier damage in murine trypanosomiasis. Am J Trop Med Hyg (2011) 0.88
4-Trimethylammonium antipyrine: a quaternary ammonium nonradionuclide marker for blood-brain barrier integrity during in vivo microdialysis. J Pharmacol Toxicol Methods (1992) 0.87
Continuous monitoring of blood-brain barrier opening to Cr51-EDTA by microdialysis following probe injury. Acta Neurochir Suppl (Wien) (1990) 0.86
Clinical follow-up in the rat experimental model of African trypanosomiasis. Exp Biol Med (Maywood) (2003) 0.85
Clinical assessment of the entry into neurological state in rat experimental African trypanosomiasis. Acta Trop (2005) 0.84
Cerebral and peripheral changes occurring in nitric oxide (NO) synthesis in a rat model of sleeping sickness: identification of brain iNOS expressing cells. PLoS One (2010) 0.82
CEREBRAL BLOOD FLOW DURING HALOTHANE ANAESTHESIA. Br J Anaesth (1963) 0.79
Evaluation of pediatric CNS malignancies with (99m)Tc-methoxyisobutylisonitrile SPECT. J Nucl Med (2002) 0.78
T cells and macrophages in Trypanosoma brucei-related glomerulopathy. Infect Immun (1994) 0.77
Pathogenesis of Trypanosoma brucei infection in deer mice (Peromyscus maniculatus). Ultrastructural pathology of the spleen, liver, heart, and kidney. Vet Pathol (1984) 0.76
Prediction of antiepileptic drug efficacy: the use of intracerebral microdialysis to monitor biophase concentrations. Expert Opin Drug Metab Toxicol (2009) 0.76
Effect of high-intensity ultrasound-targeted microbubble destruction on perfusion and function of the rat heart assessed by pinhole-gated SPECT. Ultrasound Med Biol (2010) 0.76
Does (99m)Tc-Sestamibi in high-grade malignant brain tumors reflect blood-brain barrier damage only? Neuroimage (2000) 0.76
Naturally occurring antibodies devoid of light chains. Nature (1993) 7.35
Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med (1996) 4.70
Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett (1997) 3.18
A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell (1998) 3.08
Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol (1996) 2.54
Kainate receptors are involved in synaptic plasticity. Nature (1999) 2.43
Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J (1998) 2.30
Development and testing of bioadhesive, fluoride-containing slow-release tablets for oral use. J Pharm Pharmacol (1991) 2.25
Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother (2001) 2.24
Camelid immunoglobulins and nanobody technology. Vet Immunol Immunopathol (2008) 1.90
Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol (1998) 1.67
Position and orientation of the globular domain of linker histone H5 on the nucleosome. Nature (1998) 1.62
The chemical composition of idiopathic nonarteriosclerotic cerebral calcifications. Neurology (1975) 1.59
Mapping the lectin-like activity of tumor necrosis factor. Science (1994) 1.52
Mild hypothermia induced by a helmet device: a clinical feasibility study. Resuscitation (2001) 1.51
Preferential activation of Th2 cells in chronic graft-versus-host reaction. J Immunol (1993) 1.50
Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. Eur J Immunol (1981) 1.49
Relative contribution of interferon-gamma and interleukin-10 to resistance to murine African trypanosomosis. J Infect Dis (2001) 1.46
Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem (2000) 1.38
A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops. Structure (1999) 1.36
Tumor necrosis factor alpha is a key mediator in the regulation of experimental Trypanosoma brucei infections. Infect Immun (1999) 1.36
Differential expression of H-2 gene products in tumour cells in associated with their metastatogenic properties. Nature (1980) 1.35
Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. EMBO J (2000) 1.28
Camel single-domain antibody inhibits enzyme by mimicking carbohydrate substrate. Proteins (1998) 1.26
Functional heavy-chain antibodies in Camelidae. Adv Immunol (2001) 1.22
Endurance training effects on neurotransmitter release in rat striatum: an in vivo microdialysis study. Acta Physiol Scand (1997) 1.22
The GPI-phospholipase C of Trypanosoma brucei is nonessential but influences parasitemia in mice. J Cell Biol (1997) 1.21
Homo- and heteronuclear two-dimensional NMR studies of the globular domain of histone H1: full assignment, tertiary structure, and comparison with the globular domain of histone H5. Biochemistry (1994) 1.20
Hemozoin is a key factor in the induction of malaria-associated immunosuppression. Parasite Immunol (1999) 1.20
Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem (2001) 1.15
Slender and stumpy bloodstream forms of Trypanosoma brucei display a differential response to extracellular acidic and proteolytic stress. Eur J Biochem (2000) 1.13
Interleukin-12-activated natural killer cells recognize B7 costimulatory molecules on tumor cells and autologous dendritic cells. Blood (1998) 1.12
TLR-2 and TLR-9 are sensors of apoptosis in a mouse model of doxorubicin-induced acute inflammation. Cell Death Differ (2011) 1.11
Different mechanisms account for the suppression of interleukin 2 production and the suppression of interleukin 2 receptor expression in Trypanosoma brucei-infected mice. Eur J Immunol (1989) 1.10
NMDA receptor-mediated pilocarpine-induced seizures: characterization in freely moving rats by microdialysis. Br J Pharmacol (1997) 1.10
Experimental Trypanosoma brucei infections selectively suppress both interleukin 2 production and interleukin 2 receptor expression. Eur J Immunol (1987) 1.10
Dual role of macrophages in the suppression of interleukin 2 production and interleukin 2 receptor expression in trypanosome-infected mice. Eur J Immunol (1989) 1.09
Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes? J Mol Biol (2000) 1.08
LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes. Curr Biol (1995) 1.06
The introduction of automated dispensing and injection during PET procedures: a step in the optimisation of extremity doses and whole-body doses of nuclear medicine staff. Radiat Prot Dosimetry (2010) 1.05
The in vivo and in vitro effects of antibodies against rabbit beta 2-integrins. J Immunol (1994) 1.05
The endogenous balance of soluble tumor necrosis factor receptors and tumor necrosis factor modulates cachexia and mortality in mice acutely infected with Trypanosoma cruzi. Infect Immun (1999) 1.05
Alternative versus classical macrophage activation during experimental African trypanosomosis. J Leukoc Biol (2001) 1.05
In vitro simulation of immunosuppression caused by Trypanosoma brucei: active involvement of gamma interferon and tumor necrosis factor in the pathway of suppression. Infect Immun (1996) 1.03
Degenerate interfaces in antigen-antibody complexes. J Mol Biol (2001) 1.02
The specific variable domain of camel heavy-chain antibodies is encoded in the germline. J Mol Biol (1998) 1.02
Invasiveness of T-cell hybridomas in vitro and their metastatic potential in vivo. Cancer Res (1985) 1.02
Redistribution of a murine humoral immune response following removal of an immunodominant B cell epitope from a recombinant fusion protein. Mol Immunol (1993) 1.02
Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow. Leukemia (2012) 1.02
The piglet as a model for B cell and immune system development. Vet Immunol Immunopathol (2008) 1.02
Inhibition of T-cell responsiveness during experimental infections with Trypanosoma brucei: active involvement of endogenous gamma interferon. Infect Immun (1993) 1.01
Morphological, structural and chemical study of small calcifications. Acta Neurol Belg (1974) 1.01
Stimulation and suppression of the oxygenation activity of porcine pulmonary alveolar macrophages by Actinobacillus pleuropneumoniae and its metabolites. Am J Vet Res (1992) 1.01
A role for TNF during African trypanosomiasis: involvement in parasite control, immunosuppression and pathology. Res Immunol (1993) 1.00
Emergence and evolution of functional heavy-chain antibodies in Camelidae. Dev Comp Immunol (2003) 1.00
Metastatic properties conferred on nonmetastatic tumors by hybridization of spleen B-lymphocytes with plasmacytoma cells. J Natl Cancer Inst (1981) 0.99
The invasive phenotypes. Cancer Metastasis Rev (1990) 0.99
Loss of splice consensus signal is responsible for the removal of the entire C(H)1 domain of the functional camel IGG2A heavy-chain antibodies. Mol Immunol (1999) 0.99
Tonic GABA-ergic modulation of striatal dopamine release studied by in vivo microdialysis in the freely moving rat. Eur J Pharmacol (1995) 0.99
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther (2012) 0.99
Homo- and heteronuclear two-dimensional NMR studies of the globular domain of histone H1: sequential assignment and secondary structure. Biochemistry (1993) 0.98
Identification and cloning of a glucan- and lipopolysaccharide-binding protein from Eisenia foetida earthworm involved in the activation of prophenoloxidase cascade. J Biol Chem (1998) 0.98
Murine tumour necrosis factor plays a protective role during the initial phase of the experimental infection with Trypanosoma brucei brucei. Parasite Immunol (1993) 0.98
Alterations in major histocompatibility complex phenotypes of mouse cloned T10 sarcoma cells: association with shifts from nonmetastatic to metastatic cells. J Natl Cancer Inst (1983) 0.97
The lectin-like domain of tumor necrosis factor-alpha increases membrane conductance in microvascular endothelial cells and peritoneal macrophages. Eur J Immunol (1999) 0.96
The cachexia associated with Trypanosoma cruzi acute infection in mice is attenuated by anti-TNF-alpha, but not by anti-IL-6 or anti-IFN-gamma antibodies. Parasite Immunol (1995) 0.96
Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality. Neuropsychopharmacology (2000) 0.96
ABINs inhibit EGF receptor-mediated NF-kappaB activation and growth of EGF receptor-overexpressing tumour cells. Oncogene (2008) 0.96
Formation, stability and core histone positioning of nucleosomes reassembled on bent and other nucleosome-derived DNA. J Mol Biol (1989) 0.96
Neurochemical changes and laser Doppler flowmetry in the endothelin-1 rat model for focal cerebral ischemia. Brain Res (2000) 0.94
Trypanosoma brucei infection elicits nitric oxide-dependent and nitric oxide-independent suppressive mechanisms. J Leukoc Biol (1998) 0.94
Mycobacterial proliferation in macrophages is prevented by incubation with lymphocytes activated in vitro with a mycobacterial antigen complex. Eur J Immunol (1991) 0.94
Dysfunctional astrocytic regulation of glutamate transmission in a rat model of depression. Mol Psychiatry (2012) 0.93
Nonmetastatic tumor cells acquire metastatic properties following somatic hybridization with normal cells. Cancer Metastasis Rev (1984) 0.93
Metastatic competence of BW5147 T-lymphoma cell lines is correlated with in vitro invasiveness, motility and F-actin content. J Leukoc Biol (1994) 0.93
Trypanosoma cruzi but not Trypanosoma brucei fails to induce a chemiluminescent signal in a macrophage hybridoma cell line. Infect Immun (1991) 0.93
Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int J Cancer (1998) 0.93
Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. Int J Parasitol (2008) 0.92
The peritoneal antigen-presenting macrophage: control and immunogenic properties of distinct subpopulations. Eur J Immunol (1981) 0.92
Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat. J Appl Physiol (1985) (2003) 0.92
On the existence of cytokines in invertebrates. Cell Mol Life Sci (2001) 0.91
Different residues in periplasmic domains of the CcmC inner membrane protein of Pseudomonas fluorescens ATCC 17400 are critical for cytochrome c biogenesis and pyoverdine-mediated iron uptake. Mol Microbiol (1998) 0.91
Expression of B7-1 by highly metastatic mouse T lymphomas induces optimal natural killer cell-mediated cytotoxicity. Cancer Res (1995) 0.91
Defective induction of antigen-reactive proliferating T cells in B cell-deprived mice. II. Anti-mu treatment affects the initiation and recruitment of T cells. Eur J Immunol (1983) 0.90
Postischemic mild hypothermia reduces neurotransmitter release and astroglial cell proliferation during reperfusion after asphyxial cardiac arrest in rats. Brain Res (2004) 0.90
Hippocampal and cerebellar extracellular amino acids during pilocarpine-induced seizures in freely moving rats. Eur J Pharmacol (1997) 0.90